XML 28 R17.htm IDEA: XBRL DOCUMENT
v3.19.1

Note 12 - Segment Information | 9 Months Ended
--- | ---
Mar. 31, 2019
Notes to Financial Statements |
Segment Reporting Disclosure [Text Block] | Note 12. Segment Information: The Company's management evaluates segment operating performance based on operating income before certain charges to cost of sales and selling, general and administrative expenses, principally associated with acquisition accounting related to inventory, stock based compensation, amortization of acquisition-related intangible assets and other acquisition-related expenses. The Protein Sciences and Diagnostics and Genomics reportable segments both include consumables, instruments, services and royalty revenue. The following is financial information relating to the Company's reportable segments (in thousands):
|  | Quarter Ended |  |  | Nine Months Ended |
|  | March 31, |  |  | March 31, |
|  | 201 9 |  |  | 201 8 |  |  | 201 9 |  |  | 201 8 |
Net sales: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Protein Sciences |  | $ | 137,935 |  |  | $ | 123,187 |  |  | $ | 399,787 |  |  | $ | 348,442 |
Diagnostics and Genomics |  |  | 47,134 |  |  |  | 40,929 |  |  |  | 123,144 |  |  |  | 114,604 |
Intersegment |  |  | (208 | ) |  |  | (143 | ) |  |  | (590 | ) |  |  | (307 | )
Consolidated net sales |  | $ | 184,861 |  |  | $ | 163,973 |  |  | $ | 522,341 |  |  | $ | 462,739 |
Operating income: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Protein Sciences |  | $ | 62,256 |  |  | $ | 53,813 |  |  | $ | 175,821 |  |  | $ | 150,240 |
Diagnostics and Genomics |  |  | 3,579 |  |  |  | 9,649 |  |  |  | 5,061 |  |  |  | 22,816 |
Segment operating income |  | $ | 65,835 |  |  | $ | 63,462 |  |  | $ | 180,882 |  |  | $ | 173,056 |
Costs recognized on sale of acquired inventory |  |  | (935 | ) |  |  | (1,431 | ) |  |  | (2,804 | ) |  |  | (2,013 | )
Amortization of acquisition related intangible assets |  |  | (14,400 | ) |  |  | (11,872 | ) |  |  | (43,678 | ) |  |  | (34,547 | )
Acquisition related expenses |  |  | - |  |  |  | (1,312 | ) |  |  | (2,973 | ) |  |  | (23,994 | )
Stock based compensation |  |  | (5,725 | ) |  |  | (4,748 | ) |  |  | (24,151 | ) |  |  | (13,587 | )
Corporate general, selling, and administrative expenses |  |  | (685 | ) |  |  | (1,015 | ) |  |  | (3,821 | ) |  |  | (5,652 | )
Consolidated operating income |  | $ | 44,090 |  |  | $ | 43,084 |  |  | $ | 103,455 |  |  | $ | 93,263 |

X
- References No definition available. + Details
Name: | us-gaap_DisclosureTextBlockAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -URI http://asc.fasb.org/topic&trid=2134510 + Details
Name: | us-gaap_SegmentReportingDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration